Precision Control of Transcription and Cell-Cycle Signaling: Emerging Strategies from Epigenetic Degradation to CDK-Targeted Oncology
Abstract
Recent patent disclosures highlight complementary strategies to modulate transcriptional and cell-cycle control in cancer. Selective and dual p300/CBP degraders introduce emerging epigenetic degradation modalities, while biomarker-guided CDK4 inhibition and a crystalline CDK2 inhibitor exemplify precision oncology and potential late-stage development. Together, these inventions illustrate how mechanistic innovation, patient stratification, and pharmaceutical execution converge to advance targeted anticancer therapies.
Fields of Study & Subjects
Protein Degradation and Inhibitors
Histone Deacetylase Inhibitors Research
Cancer-related Molecular Pathways
Publication details
- Journal / source
- ACS Medicinal Chemistry Letters
- Volume
- 17
- Issue
- 2
- Pages
- 302–305
- Publication date
- 11 January 2026
- Language
- EN